AZOLES AND RIFABUTIN - VORICONAZOLE
Rifabutin decreases voriconazole levels, while voriconazole dramatically increases rifabutin levels.
Concurrent use should be avoided unless the benefits are expected to outweigh the risks. The dose of voriconazole should be increased from 200 mg twice daily to 350 mg twice daily (and from 100 to 200 mg twice daily in patients under 40 kg). The intravenous dose should also be increased from 4 to 5 mg/kg twice daily. The manufacturers of voriconazole advise careful monitoring for rifabutin adverse effects (e.g. check full blood counts, monitor for uveitis).
Concurrent use should be avoided unless the benefits are expected to outweigh the risks. The dose of voriconazole should be increased from 200 mg twice daily to 350 mg twice daily (and from 100 to 200 mg twice daily in patients under 40 kg). The intravenous dose should also be increased from 4 to 5 mg/kg twice daily. The manufacturers of voriconazole advise careful monitoring for rifabutin adverse effects (e.g. check full blood counts, monitor for uveitis).